Lisata Therapeutics, Inc. (LSTA) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Lisata Therapeutics reported revenue of $170,000, down 83.0% from $1.0M the year before. Net income was -$16.6M (a -9756.5% net margin), or -$1.91 per diluted share. Operating margin was -10711.2%. Operating activities generated -$15.9M of cash, leaving -$16.0M of free cash flow. At fiscal year end, Lisata Therapeutics held $17.7M in total assets against $3.1M in total liabilities, including $16.0M of cash and equivalents.
Open the full interactive Lisata Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Lisata Therapeutics Key Stats
| Share Price | $1.08 |
|---|---|
| Market Cap | $9.8M |
| Revenue YoY Growth | -83.0% |
| 52-Week Range | $0.99 – $5.04 |
| Shares Outstanding | 9.1 million (basic, 2026 Q2) |
Lisata Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $1.0M | $170,000 |
| Operating Income | -$19.1M | -$29.1M | -$57.6M | -$25.7M | -$22.4M | -$18.2M |
| Pre-Tax Income | -$19.0M | -$29.0M | -$56.7M | -$23.2M | -$20.8M | -$17.5M |
| Income Tax | -$10.9M | -$1.5M | -$2.5M | -$2.3M | -$798,000 | -$962,000 |
| Net Income | -$8.2M | -$27.5M | -$54.2M | -$20.8M | -$20.0M | -$16.6M |
| Diluted EPS | -$7.95 | -$7.50 | -$10.47 | -$2.58 | -$2.40 | -$1.91 |
Lisata Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $100,000 | $0 | $0 |
| Net Income | -$4.2M | -$3.0M | -$4.5M | -$2.9M |
| Diluted EPS | -$0.49 | -$0.34 | -$0.50 | -$0.32 |
Lisata Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $16.5M | $24.6M | $32.2M | $22.6M | $16.2M | $16.0M |
| Current Assets | $35.3M | $96.2M | $71.9M | $53.9M | $34.6M | $17.7M |
| Total Assets | $36.0M | $97.0M | $73.0M | $54.7M | $35.0M | $17.7M |
| Current Liabilities | $3.5M | $4.5M | $6.4M | $6.6M | $5.6M | $3.1M |
| Total Liabilities | $3.8M | $5.0M | $6.7M | $6.8M | $5.7M | $3.1M |
| Shareholders' Equity | $32.5M | $92.3M | $66.6M | $48.1M | $29.6M | $14.9M |
Lisata Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$8.8M | -$22.2M | -$21.2M | -$20.0M | -$19.4M | -$15.9M |
| Cash From Investing | -$7.3M | -$54.9M | $28.9M | $10.1M | $13.2M | $15.1M |
| Cash From Financing | $18.6M | $85.3M | -$224,000 | $385,000 | -$206,000 | $599,000 |
| Free Cash Flow | -$8.8M | -$22.3M | -$21.5M | -$20.0M | — | -$16.0M |
Figures from Lisata Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Lisata Therapeutics financials page for every line item.
Lisata Therapeutics Company Profile
| Ticker | LSTA |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Basking Ridge, New Jersey |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0000320017 |
Frequently Asked Questions
What was Lisata Therapeutics' revenue in fiscal 2025?
Lisata Therapeutics (LSTA) reported revenue of $170,000 for fiscal 2025.
What is Lisata Therapeutics' annual revenue history?
Lisata Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $1.0M; 2025: $170,000.
What was Lisata Therapeutics' net income in fiscal 2025?
Lisata Therapeutics reported net income of -$16.6M for fiscal 2025.
What was Lisata Therapeutics' earnings per share (EPS) in fiscal 2025?
Lisata Therapeutics' diluted EPS was -$1.91 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Lisata Therapeutics generate in fiscal 2025?
Lisata Therapeutics generated -$16.0M of free cash flow in fiscal 2025.
What was Lisata Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Lisata Therapeutics reported revenue of $0.
How many shares of Lisata Therapeutics are outstanding?
Lisata Therapeutics reported a weighted average of 9.1 million basic shares outstanding in 2026 Q2.
What is Lisata Therapeutics' market cap?
Based on its latest closing price, Lisata Therapeutics (LSTA) has a market capitalization of about $9.8M.
When does Lisata Therapeutics' fiscal year end?
Lisata Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Lisata Therapeutics headquartered?
Lisata Therapeutics lists its business address in Basking Ridge, New Jersey in its SEC filings.